Sun Kim, MD
Urology · San Bernardino, CANPI 1093738932
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), speaking fees and education — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Neotract Inc. at 32.7% of the total. Reporting peaked in 2019 at $9,993 and has fallen 87.5% since, to $1,248 in 2025.
Across 360 payments — averaging $50.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$6K
- Intuitive Surgical$3K
- Johnson & Johnson$2K
- AbbVie$1K
- Teleflex LLC$1K
- Boston Scientific$521
- plus $4K from 45 others
Across 17 payments — averaging $1735.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$29K
What the payments were for
- Consulting fees$7584%
- Speaking & faculty fees$4,70026%
- Travel & lodging$9315%
- Food & beverage$8,60947%
- Education$3,31118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$5,560
- Da Vinci Surgical System$3,000
- Erleada$981
- ALTIS$198
- INTERSTIM$175
- UroLift System$142
- BIODRESTORE$131
- BIODOPTIX$131
- LithoVue$129
- AKEEGA$120
- Dornier MedTech$105
- AMS$101
- PYLARIFY$101
How this compares
$18,308 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lupron DepotLeuprolide Acetate | 88 | $456,992 |
| MyrbetriqMirabegron | 571 | $422,106 |
| GemtesaVibegron | 147 | $116,769 |
| TrelstarTriptorelin Pamoate | 49 | $105,256 |
| OrgovyxRelugolix | 16 | $43,109 |
| Tamsulosin Hcl | 2,130 | $24,940 |
| Finasteride | 1,763 | $20,419 |
| EligardLeuprolide Acetate | 15 | $19,569 |
| Oxybutynin Chloride ErOxybutynin Chloride | 505 | $12,325 |
| Mirabegron ErMirabegron | 12 | $9,670 |
| Cephalexin | 282 | $5,538 |
| Solifenacin Succinate | 44 | $4,833 |
| Tadalafil | 20 | $4,002 |
| Doxazosin Mesylate | 261 | $3,426 |
| Testosterone | 13 | $3,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLupron Depot | $1,306 | $456,99288 claims |
| Astellas Pharma US IncMyrbetriq | $391 | $422,106571 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $222 | $159,878163 claims |
| Verity Pharmaceuticals Inc.Trelstar | $283 | $105,25649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.
Other urology in San Bernardino
- Avinash ChenamSan Bernardino$75K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.